|
TaqMan qRT-PCR analysis of 6 candidate miRNAs in serum from 25 mPC patients and 25 HI. Normalised to spike-ins.
|
miR-141
|
AUC = 0.907, Sn = 60 %, Sp = 100 %
|
Mitchell et al. 2008 [11]
|
|
miRNA profiling by in serum from 6 PC patients (stage 3 and 4) and 8 HI by pan-miRNA microarray.
|
miR-16, miR-34b, miR-92a, miR-92b, miR-103, miR-107, miR-197, miR-328, miR-485-3p, miR-486-5p, miR-574-3p, miR-636, miR-640, miR-766, miR-885-5p
|
Upregulated miRNA levels in PC serum samples
|
Lodes et al. 2009 [118]
|
|
qRT-PCR analysis of 3 candidate miRNAs in plasma from 51 PC patients (26 LPC, 25mPC) and 20 HI. Normalized to RNU1A.
|
miR-21, miR-141, miR-221
|
miR-21: AUC = 0.880 (PC vs HI)
|
Agaoglu et al. 2011 [119]
|
|
miR-221: AUC = 0.830 (PC vs HI)
|
|
miR-141: AUC = 0.755 (mPC vs LPC)
|
|
Discovery: profiling of 667 miRNAs in serum of 7 mPC and 14 LPC patients by TaqMan arrays. Normalised to spike-ins.
|
miR-141, miR-200b, miR-375
|
69 differentially expressed miRNAs between mPC and LPC.
|
Brase et al. 2011 [120]
|
|
Validation 1: analysis of 5 selected miRNA in different PC risk groups (n = 45).
|
Increased miR-375, miR-141, miR-200b levels differentiate pT3 vs pT2, Gleason score 6 vs 7.
|
|
Validation 2: analysis of 3 selected miRNA in different PC risk groups (n = 71).
|
miR-375 level differentiate Gleason score 7 vs ≥8 and N0 vs N1/M+
|
|
qRT-PCR analysis of 4 candidate miRNAs in serum from 45 PC, 18 BPH patients and 20 HI. Normalised to spike-ins.
|
let-7i, miR-26a, miR-32, miR-195
|
4 miRNA model: AUC = 0.758, Sn = 78,4 %, Sp = 66.7 % (LPC vs BPH) (PSA AUC = 0.834)
|
Mahn et al. 2011 [121]
|
|
Decrease of miR-26a and miR-195 level after prostatectomy
|
|
Profiling of 384 miRNAs in serum from 36 PC patients (CAPRA scores: 12 low, 12 medium, 12 high risk) and 12 HI using Fluidigm microfluidic platform, validation of 12 candidate miRNAs by qRT-PCR in the same sample set.
|
miR-24, miR-26b, miR-30c, miR-93, miR-106a, miR-223, miR-451, miR-874, miR-1207-5p, miR-1274a
|
10 differentially expressed miRNAs (PC vs HI)
|
Moltzhan et al. 2011 [100]
|
|
miR-106a, miR-93, miR-1274: a liner relationship between increased miRNA level and increased risk score.
|
|
miR-24: a liner relationship between decreased miRNA level and increased risk score.
|
|
miR-451: increased in high risk in comparison to low and medium risk PC and HI.
|
|
qRT-PCR analysis of miR-21 in serum from 56 patients (20 LPC, 20 ADPC, 10 CRPC and 6 BPH) The 10 CRPC patients received docetaxel-based chemotherapy.
|
miR-21
|
A liner relationship between increased miR-21 level and increased serum PSA level in patients with ADPC and HRPC.
|
Zhang et al. 2011 [122]
|
|
Higher miR-21 levels in patients who were resistant to docetaxel-based chemotherapy.
|
|
Profiling of 742 miRNAs in plasma-derived MVs from 78 PC patients (55 LPC, 16 mPC) and 28 HI using Exiqon miRNA qPCR panel. Validation of miR-375 and miR-141 in MV and exosome fractions from sera of 47 mPC and 72 non-recurrent PC patients by TaqMan qRT-PCR. Normalised to spike-ins.
|
27 differentially expressed miRNAs
|
miR-107, miR-130b, miR-141, miR-181a-2*, miR-2110, miR-301a, miR-326, miR-331-3p, miR-432, miR-574-3p, miRr-625* (PC vs HI).
|
Bryant et al. 2012 [106]
|
|
miR-107, miR-141, miR-181a-2*, miR-2110, miR-301a, miR-326, miR-432, miR-574-3p, miR-625* (LPC vs HI).
|
|
miR-17*, miR-20a*, miR-23a*, miR-130b, miR-198, miR-200b, miR-375, miR-379, miR-513a-5p, miR-572, miR-577, miR-582-3p, miR-609, miR-619, miR-624*, miR-1236 (mPC vs LPC)
|
|
Discovery: profiling of 754 miRNAs in plasma from 25 PC and 17 BPH patients by Illumina miRNA expression platform. Validation: qRT-PCR analysis of 8 selected miRNAs in plasma from 80 PC, 44 BPH and 54 HI. Normalised to U6.
|
let-7c, let-7e, miR-30c, miR-622, miR-1285
|
5 miRNA model: AUC = 0.860, Sn = 74.1 %, Sp = 83.8 % (PC vs HI)
|
Chen et al. 2012 [96]
|
|
AUC = 0.924 (PC vs BPH)
|
|
Profiling of 365 miRNAs in serum from 25 mCRPC patients (pooled) and 25 HI (pooled) by TaqMan Low-Density Array. Normalised to spike-ins. Additional testing of individual miRNAs by TaqMan qRT-PCR.
|
miR-141, miR-200a, miR-200c, miR-210, miR-375
|
Increased miRNA levels in serum samples from mCRPC patients
|
Cheng et al. 2013 [103]
|
|
miR-210: correlation with PSA response to treatment
|
|
Profiling of 699 miRNAs in serum samples from 28 patients of low-risk LPC and 26 of mCRPC by TaqMan microRNA arrays.
|
miR-141, miR-375, miR-378*, miR-409-3p
|
Increased levels of miR-375, miR-378* and miR-141; decreased level of miR-409-3p (mCRPC vs LPC)
|
Nguyen et al. 2013 [117]
|
|
miRNA profiling in the serum of 8 patients with rapid BCR and 8 patients without BCR following RP. Validation: Testing of four candidate miRNAs in 70 independent Gleason 7 PC patient serum samples, 31 of whom had relapse after RP, by qRT-PCR.
|
miR-141, miR-146b-3p, miR-194
|
Increased miRNA levels in serum samples from patients who had experienced BCR.
|
Selth et al. 2013 [99]
|
|
miR-146b-3p (HR = 2.13) and miR-194 (HR = 2.13) were also associated with disease progression in the validation cohort.
|
|
qRT-PCR analysis of 4 miRNAs (previously found deregulated in PC tissues) in urine samples from 36 PC patients (GS6 and GS7) and 12 HI. Normalised to RNU48.
|
miR-205, miR-214
|
Decreased miRNA levels in PC. miR-205: AUC = 0.708, miR-214: AUC = 0.743
|
Srivastava et al. 2013 [15]
|
|
2 miRNA model: Sn = 89 %, Sp = 80 %
|
|
Profiling of 742 miRNAs in plasma samples from 25 LPC (pooled) and 25 mCRPC (pooled) patients by Exiqon miRNA qPCR panel. Validation: Analysis of 10 selected candidate miRNAs in 50 individual plasma samples by qRT-PCR.
|
miR-16, miR-141, miR-151-3p
|
67 differentially expressed miRNAs.
|
Watahiki et al. 2013 [98]
|
|
3 miRNA model : AUC = 0.944, Sn = 84 %, Sp = 96 %
|
|
Profiling of 732 miRNAs in serum samples from 13 BPH and 31 PC (11 LPC + 9 N1/M1 + 11 CRPC) patients by Exiqon microRNA PCR panel I + II, V2.M.
|
19 differentially expressed miRNAs
|
miR-562/miR-210/miR-501-3p/miR-375/miR-551b model: AUC = 0.919, Sn = 84 %, Sp = 100 % (BPH vs PC)
|
Haldrup et al. 2014 [97]
|
|
miR-375/miR-708/miR-1203/miR-200a model: AUC = 0.875, Sn = 75 %, Sp = 100 % (LPC vs disseminated PC)
|
|
let-7a/miR-210/miR-562/miR-616/miR-297 model: AUC = 0.900, Sn = 80 %, Sp = 100 % (BPH vs disseminated PC)
|
|
miRNA profiling on docetaxel-resistant and sensitive cell lines to identify candidate circulating miRNA biomarkers and subsequent qRT-PCR analysis of 46 candidate miRNAs in plasma/serum samples collected from 97 CRPC patients before and after docetaxel treatment.
|
miR-20a, miR-20b, miR-21, miR-25, miR-132, miR-146a, miR-200a, miR-200b, miR-200c, miR-201b, miR-222, miR-375, miR-429, miR-590-5p
|
miR-200c/miR-200b/miR-146a/miR-222/miR-201b/miR-20a model for prediction of chemoresponse: AUC = 0.730
|
Lin et al. 2014 [102]
|
|
Pre-docetaxel levels of miR-200b, miR-429, miR-200a, miR-21, miR-200c, miR-590-5p, miR-375, miR-132, miR-20a and post-docetaxel decrease/no-change of miR-20a, miR-222, miR-20b, miR-132 and miR-25 associated with poor overall survival.
|
|
miRNA profiling in PSS from 4 BPH patients and 4 PC patients by Agilent miRNA Microarray.
|
miR-133b, miR- 203, miR-221, miR-361-3p
|
4 miRNA model: AUC = 0.950
|
Guzel et al. 2015 [14]
|
|
Validation: Analysis of 4 candidate miRNA in PSS from 23 PC and 25 BPH patients by qRT-PCR.
|
|
Deep sequencing of plasma exosomal RNA in 23 CRPC patients and correlation with OS. Validation: qRT-PCR analysis of candidate miRNAs in a follow-up cohort of 100 CRPC patients.
|
miR-375, miR-1290
|
miRNA levels significantly associated with poor overall survival.
|
Huang et al. 2015 [107]
|
|
Combination of ADT failure time and PSA level at time of CRPC stage with miRNA levels improved predictive performance with AUC increase from 0.660 to 0.730.
|
|
qRT-PCR analysis of 12 miRNAs in blood and tissue samples from 75 PC and 27 BPH patients
|
let-7a, miR-141, miR-145, miR-155
|
4 miRNA model: AUC = 0.783, Sn = 97 %, PPV = 80 %
|
Kelly et al. 2015 [123]
|
|
qRT-PCR analysis of 3 candidate miRNAs in cell-free urine fraction from 71 PC patients and 18 HI.
|
miR-483-5p
|
Elevated miRNA levels in PC patients, AUC = 0.694
|
Korzeniewski et al. 2015 [57]
|
|
Discovery: miRNA profiling in cell-free urine from 14 PC and 5 BPH patients. Validation: qRT-PCR analysis of candidate miRNAs in urine in 3 validation cohorts including 593 PC patients and 459 controls.
|
Hsv1-miR-H18, hsv2-miR-H9-5p
|
Hsv1-miR-H18: AUC = 0.772, Sn = 66.5 %, Sp = 74.1 %
|
Yun et al. 2015 [104]
|
|
Hsv2-miR-H9-5p: AUC = 0.777, Sn = 70.2 %, Sp = 72.0 %
|
|
qRT-PCR analysis of 21 miRNA in serum from 50 low-grade (Gleason grade 3) PC and 50 high grade (Gleason grade 4 + 5) PC.
|
let-7a, miR-24, miR-26b, miR-30c, miR-93, miR-100, miR-103, miR-106a, miR-107, miR-130b, miR-146a, miR-223, miR-451, miR-874
|
Highly expressed in BPH and low-grade PC, uniformly low levels in high-grade PC. 11 miR model: NPV of 0.939 for prediction of absence of high-grade PC.
|
Mihelich et al. 2015 [101]
|
